Swiss biotech Novimmune has closed a $66 million B round to bankroll its broad pipeline of monoclonal antibodies, and one of the company’s lead investors told a local newspaper that it’s considering going public to further finance its projects.

…read more

Source: Novimmune banks $66M for immunotherapies as IPO rumors surface


0 No comments